Evgen Pharma Share Discussion Threads

[bernymadoff] 01/5/2018 12:46

The sellers are likely placees from the 12p raise last December. Unfortunately we don't know how many of them are sticky (maybe institutions) and how many are flippers. There certainly seems to be some flippers about but what's encouraging is that they are offloading at 20p and over. There doesn't seem to be much appetite to sell for less. It's just a waiting game now. The increasing volumes we have been seeing of late will eat away the overhang and if we get positive interims it will generate a huge amount of interest and buying as everyone jumps in for the full readouts for both trials due around the end of the year. Add if you can as this is still very much ground floor. Once the flippers are gone it will move up to the 30s in a flash

[nico115] 01/5/2018 12:32

I'm a little crazyI like to perfect my timing and not sure where we bottom 15 to 17p..feels like sellers on every rise

[bernymadoff] 01/5/2018 12:17

Nicola, are you hormonal or just bipolar?

[shirley83] 01/5/2018 12:16

Small sells big buys..

[nico115] 01/5/2018 12:09

I'm still not convicted as won't hit 15p so am saving some ammoStill think bit of hot money in here Needs some indigestion around here

[metis20] 01/5/2018 10:31

Safety - this extract from the Admission Document -

The Directors believe the Group has a lower risk profile for an early stage drug development company because

* there is a wealth of published peer-reviewed scientific papers regarding the anti-cancer and anti-inflammatory properties of sulforaphane, the active molecule within SFX-01;

* SFX-01 has been demonstrated by the Group to be safe and well tolerated, with excellent bioavailability in trials on healthy human volunteers

[timbo003] 01/5/2018 10:15

>>>Chesty

I think it is very unlikely that results are "bad" as the ongoing study is primarily a safety study and there is no control group in which SFX-01 is not included (see link in header for trial design on clintrials.gov), so it will not be possible to make any comparisons of patient outcomes with and without SFX-01.

If there were significant safely issues, we would have heard about them by now, furthermore we know that some patients have opted to continue with the treatment with SFX-01 when the formal treatment period was complete (compassionate use)which must be a good sign.

This interim read out should give us more info on the safety profile, the mortality rates and progression rates, which will no doubt be compared with safety, mortality and progression rates from other studies where patients with MBC that has reached a similar stage have been treated with aromatase inhibitors (AIs), tamoxifen and fulvestrant (without the addition of SFX-01)

[metis20] 01/5/2018 10:14

From Dec.2017 Hardman report -

Seven sites are now open for recruitment across the UK, Spain and Belgium. Given that the trial is ‘open label’, Evgen is projecting that interim data from at least one of the cohorts will be available in 1H 2018, with the final trial read-out towards the end of 2018.

[nico115] 01/5/2018 10:06

Chesty Yes this is risky but this is not the actual phase 2 so I expect the upcoming results to be positive

[metis20] 01/5/2018 10:06

Positive test results by June will push share price considerably above the IPO price.

IMO institutions did not buy in to the IPO to see the value of their holdings be unchanged on the delivery of positive test results.

[metis20] 01/5/2018 10:00

So between 11th Dec 2017 (Hardman update) and 18th Jan 2018 - a period when the share price was 14p - 15.5p -

Seneca EVG holding up from 3.8% to 7.4%

Axa EVG holding up from 7% to 9.2%

[chesty1] 01/5/2018 09:53

Nico what if results are bad like imm what price then ?

[nico115] 01/5/2018 09:51

Still of the view Instit bought at 12p not higher And topinfo ramping However I do think if we get positive test results by June these will be at IPo price of 37p

[timbo003] 01/5/2018 09:34

Worth noting that in December Beaufort held >2% of the shares (see link to December Hardman note in the header). I don't know what they hold now, as we haven't had a Hardman update since, but could the unwinding of that position have been a major cause of the share price weakness earlier this year?

[nico115] 01/5/2018 09:22

Yes Berney I was always bullish but was hoping to buy more at 15pHad a change of heart today after reading the northland note and have bought 100k shares at 18.5Got 400k now ..leaving small ammo for 15p but if we hold today think it's mid 20s again

[bernymadoff] 01/5/2018 09:13

You cant hold back the tide. Even Nico has been forced to increase his buy in price lmfao

[nico115] 01/5/2018 09:05

Yes Shirley Was v frothy but if we hold these levels today my technicals say a retest of 25p is on the cards I would much rather buy at 15 to 17p than all the P and D who chase charts and bought evg in mid 20sBuy red sell blue Rinse repeat

[shirley83] 01/5/2018 09:00

Told you higher lows as more people realise the potential and add

[nico115] 01/5/2018 08:48

Looks like we are forming a base here at 17pBottom of range should be 15 to 17p and top should be 25p until we get some news out within the next 8 weeks

[nico115] 30/4/2018 21:18

17 to 15 is but a mere whisker away Tomorrow maybe the day And I'm a poet And I didn't even know it

[shirley83] 30/4/2018 20:35

15p long gone.. Higher lows as more people stay in for the multi bagger..

[metis20] 30/4/2018 20:30

Major institutional shareholders as at 18th Jan 2018 (no shareholding RNSs since then).

North West Fund(Biomedical)LP 17.35% no change since IPO
RisingStars Growth Fund LP II 12.81% no change since IPO
AXA Framlington Investment Management 9.15% up by about 1/3 since IPO
Seneca Partners Limited 7.37% almost doubled since IPO
South Yorkshire Investment Fund Limited 4.04% no change since IPO
Sarum Investment SICAV Plc 3.22% no change since IPO

The change comments refer to number of shares.

[nico115] 30/4/2018 20:27

But at 15p sell at 25p until the read out in May JuneWe fell in decent volume which means we should fall back to 15p

[l0ngterm] 30/4/2018 20:17

If the interim results have no ambiguity (then tick), if the company finds a partner then ( tick). No comparison from then on with IMM, please folks. I was in BTG did well, was in IMM not as good as I liked. But if the chicken wants paid, it has to forget about yesterday's near miss and cross the road. Otherwise buy into a bond or a fund. Soz It's been a long day lol, but things seems to be taking shape here. GLA.